DENVER, May 01, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare…
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for…
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has…
RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing…
With funding, ODAIA to fuel expansion and support the rapid growth of its AI-powered solutions that help pharma companies put…
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two…
OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) launches its month-long Sun Awareness Month campaign, urging…
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group,…
Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S.…
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients…